-
1.发明公开公开(公告)号：US20240058450A1
公开(公告)日：2024-02-22
申请号：US17804696
申请日：2022-05-31
Applicant: AbbVie Inc.
Inventor： Scott L. Ackler , Nathan B. Bennett , Erwin R. Boghaert , Steve C. Cullen , George Doherty , Robin R. Frey , Anthony R. Haight , Andrew S. Judd , Aaron R. Kunzer , Violeta L. Marin , Xiaoqiang Shen , Xiaohong Song , Andrew J. Souers , Gerard M. Sullivan , Zhi-Fu Tao , Xilu Wang , Dennie S. Welch , Michael D. Wendt
IPC: A61K45/06 , C07D417/14 , C07D513/04 , A61K47/68 , A61K31/4709 , A61K31/4725 , A61K31/498 , A61K31/4985 , A61K31/538 , C07D487/04
CPC classification number: A61K45/06 , C07D417/14 , C07D513/04 , A61K47/6889 , A61K47/6803 , A61K47/6849 , C07D487/04 , A61K47/6883 , A61K31/4709 , A61K31/4725 , A61K31/498 , A61K31/4985 , A61K31/538 , A61K47/6851
Abstract: The present disclosure concerns Bcl-xL inhibitors having low cell permeability, antibody drug conjugates (ADCs) comprising the inhibitors, synthons useful for synthesizing the ADCs, compositions comprising the inhibitors or ADCs, and various methods of using the inhibitors and ADCs.
-
公开(公告)号：US20140093521A1
公开(公告)日：2014-04-03
申请号：US14090778
申请日：2013-11-26
Applicant: ABBVIE INC.
Inventor： Lorenzo Benatuil , Erwin R. Boghaert , Jijie Gu , Maria Harris , Jonathan A. Hickson , Chung-Ming Hsieh , Yuliya Kutskova , Yingchun Li , Zhihong Liu , Susan Morgan-Lappe
IPC: A61K39/395 , A61K45/06 , C07K16/18 , C07K7/06 , C07K7/08
CPC classification number: C07K16/22 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K7/06 , C07K7/08 , C07K14/47 , C07K16/18 , C07K2317/21 , C07K2317/33 , C07K2317/565 , C07K2317/567 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2317/94
Abstract: Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis.
Abstract translation: 描述了改进的DLL4结合蛋白，包括抗体，CDR-移植抗体，人抗体和DLL4结合片段，以高亲和力结合DLL4的蛋白质，以及中和DLL4活性的DLL4结合蛋白。 DLL4结合蛋白可用于治疗或预防癌症和肿瘤，特别是用于治疗或预防肿瘤血管生成和/或其它血管发生依赖性疾病，例如眼新生血管形成或以异常DLL4表达或活性为特征的血管发生非依赖性疾病，例如自身免疫 包括多发性硬化的疾病。
-
公开(公告)号：US20240199745A1
公开(公告)日：2024-06-20
申请号：US18349904
申请日：2023-07-10
Applicant: AbbVie Inc.
Inventor： Erwin R. Boghaert , Milan Bruncko , George Doherty , Robin R. Frey , Andrew S. Judd , Andrew C. Phillips , Xiaohong Song , Andrew J. Souers , Gerard M. Sullivan , Zhi-Fu Tao
CPC classification number: C07K16/2863 , A61K47/65 , A61K47/6803 , A61K47/6845 , A61K47/6849 , A61K47/6855 , A61K47/6857 , A61K47/6889 , A61P35/00 , A61K2039/505 , A61K2039/545 , A61K45/06 , C07K16/22 , C07K16/2827
Abstract: The invention relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods of using said ADCs.
-
公开(公告)号：US20180371071A1
公开(公告)日：2018-12-27
申请号：US15582065
申请日：2017-04-28
Applicant: AbbVie Inc.
Inventor： Lorenzo Benatuil , Erwin R. Boghaert , Jijie Gu , Maria Harris , Jonathan A. Hickson , Chung-Ming Hsieh , Yuliya Kutskova , Yingchun Li , Zhihong Liu , Susan Morgan-Lappe
Abstract: Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis.
-
公开(公告)号：US20160060332A1
公开(公告)日：2016-03-03
申请号：US14822329
申请日：2015-08-10
Applicant: Abbvie Inc.
Inventor： Lorenzo Benatuil , Erwin R. Boghaert , Jijie Gu , Maria Harris , Jonathan A. Hickson , Chung-Ming Hsieh , Yuliya Kutskova , Yingchun Li , Zhihong Liu , Susan Morgan-Lappe
IPC: C07K16/22
CPC classification number: C07K16/22 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K7/06 , C07K7/08 , C07K14/47 , C07K16/18 , C07K2317/21 , C07K2317/33 , C07K2317/565 , C07K2317/567 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2317/94
Abstract: Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis.
Abstract translation: 描述了改进的DLL4结合蛋白，包括抗体，CDR-移植抗体，人抗体和DLL4结合片段，以高亲和力结合DLL4的蛋白质，以及中和DLL4活性的DLL4结合蛋白。 DLL4结合蛋白可用于治疗或预防癌症和肿瘤，特别是用于治疗或预防肿瘤血管生成和/或其它血管发生依赖性疾病，例如眼新生血管形成或以异常DLL4表达或活性为特征的血管发生非依赖性疾病，例如自身免疫 包括多发性硬化的疾病。
-
Patent Agency Ranking
公开(公告)号：US20240115725A1
公开(公告)日：2024-04-11
申请号：US18506459
申请日：2023-11-10
Applicant: AbbVie Inc.
Inventor： Erwin R. Boghaert , Andrew C. Phillips , Andrew J. Souers , Kamel Izeradjene , John E. Harlan
CPC classification number: A61K47/6849 , A61K47/6803 , A61P35/00 , C07K16/2863 , A61K2039/505
Abstract: The present disclosure relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods using such ADCs, and methods for making such ADCs.
-
公开(公告)号：US20230372519A1
公开(公告)日：2023-11-23
申请号：US18181450
申请日：2023-03-09
Applicant: AbbVie Inc.
Inventor： Andrew C. Phillips , Regina M. Reilly , George A. Doherty , Cheng Ji , Milan Bruncko , Erwin R. Boghaert , Mark Anderson
IPC: A61K47/68 , C07K16/28 , A61P35/00 , C07D491/22 , C07K5/068
CPC classification number: A61K47/6849 , C07K16/2863 , A61K47/6803 , A61P35/00 , C07D491/22 , C07K5/06086 , C07K2317/73 , C07K2317/565 , A61K2039/505
Abstract: The present disclosure provides c-Met antibody drug conjugates (ADCs), including compositions and methods of using such ADCs.
-
公开(公告)号：US11633497B2
公开(公告)日：2023-04-25
申请号：US17661450
申请日：2022-04-29
Applicant: AbbVie Inc.
Inventor： Andrew C. Phillips , Regina M. Reilly , George A. Doherty , Cheng Ji , Milan Bruncko , Erwin R. Boghaert , Mark Anderson
Abstract: The present disclosure provides c-Met antibody drug conjugates (ADCs), including compositions and methods of using such ADCs.
-
公开(公告)号：US11759527B2
公开(公告)日：2023-09-19
申请号：US17580134
申请日：2022-01-20
Applicant: AbbVie Inc.
Inventor： Erwin R. Boghaert , Andrew C. Phillips , Andrew J. Souers , Kamel Izeradjene , John E. Harlan
CPC classification number: A61K47/6849 , A61K47/6803 , A61P35/00 , C07K16/2863 , A61K2039/505 , C07K2317/73 , C07K2317/92
Abstract: The present disclosure relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods using such ADCs, and methods for making such ADCs.
-
公开(公告)号：US20230114718A1
公开(公告)日：2023-04-13
申请号：US17688908
申请日：2022-03-08
Applicant: AbbVie Inc.
Inventor： Erwin R. Boghaert , Milan Bruncko , Andrew S. Judd , Andrew C. Phillips , Andrew J. Souers
IPC: C07K16/28 , A61K47/68 , A61K47/65 , A61P35/00 , A61K31/5377
Abstract: The invention relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods of using said ADCs.
-
-
-
-
-
-
-
-
-
Search Results
23
records
(took 0.024 seconds)
